DISCO PHARMACEUTICALS
Live / Applied — Suspended — suspension letter mailed (as of 03 Nov 2025)
What this means for you
Not registered yet, but its 13 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79411970
- Mark type
- Design + words
- Filed
- 13 Jun 2024
- Attorney of record
- Christopher M. Kindel
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of pharmaceuticals for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; biomolecules, in particular biological macromolecules, namely, proteins for use in the manufacture of pharmaceuticals; all the foregoing for scientific and industrial purposes for the human pharmaceutical industry and excluding products for biomedical research and testing.
- Class 005 — Pharmaceuticals: Chemical preparations for medical use, namely, for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; immunostimulatory compositions being pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; vaccines; adjuvant immunostimulants, namely, adjuvants for medical purposes; pharmaceuticals and medicines based on biological micromolecules for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceuticals and medicines, namely, enzymes and proteins for medical use in protein and enzyme replacement therapy; Pharmaceutical preparations for gene therapy for the treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; all of the foregoing excluding nutritional supplements, phytotherapy preparations for medical purposes, and products for biomedical research and testing
- Class 042 — Scientific and technological services: Scientific and technological services and research services, in particular for identifying and characterizing biological macromolecules, namely, biological and chemical research and analysis; development of pharmaceuticals preparations or vaccines; conducting of and scientific support for preclinical or clinical studies, namely, scientific research in the nature of conducting pre-clinical and clinical trials for others; all of the foregoing excluding products for biomedical research and testing
- Class 044 — Medical, beauty and agricultural services: Medical services, in particular for therapeutic and preventative treatment of tumours, infectious diseases, autoimmune disorders and allergies, for treating inherited genetic diseases and for protein and enzyme replacement therapy, and for treating neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treating metabolic disorders
Owner
Prosecution history
- 03 Nov 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 03 Nov 2025 — LETTER OF SUSPENSION E-MAILED
- 03 Nov 2025 — SUSPENSION LETTER WRITTEN
- 05 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 27 Jun 2025 — ATTORNEY REVIEW COMPLETED
- 25 Jun 2025 — CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
- 22 Feb 2025 — REFUSAL PROCESSED BY IB
- 05 Feb 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 05 Feb 2025 — REFUSAL PROCESSED BY MPU
- 31 Dec 2024 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 30 Dec 2024 — NON-FINAL ACTION WRITTEN
- 21 Dec 2024 — CORRECTION TRANSACTION RECEIVED FROM IB
- 18 Dec 2024 — ASSIGNED TO EXAMINER